By Shalini Bhardwaj

New Delhi [India] June 15 (ANI): The first indigenously developed quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer by the Serum Institute of India (SII) will be discussed by the Subject expert committee on Wednesday.

Also Read | Rahul Sahu, 11-Year-Old Boy Who Had Fallen into Borewell in Chhattisgarh’s Janjgir Champa, Rescued After 104 Hours (Watch Video).

The application for market authorization of the qHPV vaccine was submitted to the DCGI on June 8 by Prakash Kumar Singh (director of government and regulatory affairs).

The application to the DCGI by Singh mentions the antibody response of the vaccine against HPV types in all dose and age groups.

Also Read | Religious Conversion: Law Should Not Be Weak So Culprits Could Escape, Says Goa CM Pramod Sawant.

The vaccine is expected to be launched in the market before the end of 2022, sources told ANI. The qHPV will be India's first indigenously curated vaccine against cervical cancer.

To ensure its early availability in the country, the Pune-based Serum Institute of India has applied for market authorization after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)